S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10

Apollo Medical (AMEH) Stock Forecast, Price & News

+1.06 (+2.98%)
(As of 05/27/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
148,143 shs
Average Volume
254,228 shs
Market Capitalization
$2.05 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive AMEH News and Ratings via Email

Sign-up to receive the latest news and ratings for Apollo Medical and its competitors with MarketBeat's FREE daily newsletter.

Apollo Medical logo

About Apollo Medical

Apollo Medical Holdings, Inc., a physician-centric technology-powered healthcare company, provides medical care services. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The company's physician network consists of primary care physicians, specialist physicians, and hospitalists. It serves patients, primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organization plans; and non-insured patients in California. The company was founded in 1994 and is headquartered in Alhambra, California.


See More Headlines

Industry, Sector and Symbol

Management consulting services
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$773.91 million
Cash Flow
$1.66 per share
Book Value
$8.56 per share


Net Income
$73.86 million
Pretax Margin




Free Float
Market Cap
$2.05 billion
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.62 out of 5 stars

Medical Sector

966th out of 1,427 stocks

Management Consulting Services Industry

16th out of 27 stocks

Analyst Opinion: 3.3Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Apollo Medical (NASDAQ:AMEH) Frequently Asked Questions

Is Apollo Medical a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Apollo Medical in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Apollo Medical stock.
View analyst ratings for Apollo Medical
or view top-rated stocks.

When is Apollo Medical's next earnings date?

Apollo Medical is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Apollo Medical

How were Apollo Medical's earnings last quarter?

Apollo Medical Holdings, Inc. (NASDAQ:AMEH) released its earnings results on Thursday, May, 5th. The company reported $0.31 EPS for the quarter. The company had revenue of $263.26 million for the quarter. Apollo Medical had a trailing twelve-month return on equity of 16.80% and a net margin of 8.71%.
View Apollo Medical's earnings history

What guidance has Apollo Medical issued on next quarter's earnings?

Apollo Medical updated its FY 2022 earnings guidance on Monday, May, 23rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.05 billion-$1.08 billion, compared to the consensus revenue estimate of $1.05 billion.

What price target have analysts set for AMEH?

2 brokerages have issued twelve-month price objectives for Apollo Medical's shares. Their forecasts range from $75.00 to $92.00. On average, they expect Apollo Medical's share price to reach $83.50 in the next twelve months. This suggests a possible upside of 128.0% from the stock's current price.
View analysts' price targets for Apollo Medical
or view top-rated stocks among Wall Street analysts.

Who are Apollo Medical's key executives?
Apollo Medical's management team includes the following people:
  • Dr. Kenneth T. Sim M.D., Exec. Chairman (Age 68, Pay $1.07M)
  • Dr. Thomas S. Lam M.D., M.P.H., Pres, Co-CEO & Director (Age 73, Pay $1.07M)
  • Mr. Brandon Sim, Co-Chief Exec. Officer (Age 28, Pay $131.05k) (LinkedIn Profile)
  • Mr. Eric Chin, CFO & Corp. Sec. (Age 42, Pay $318.55k)
  • Dr. WaiChow Young M.D., Chief Admin. Officer (Age 75, Pay $382.04k)
  • Dr. Jeremy R. Jackson M.D., Chief Quality Officer
  • Mr. Neil Ahuja, Pres of Provider Solutions
  • Yubin Park, Chief Analytics Officer
What is Thomas Lam's approval rating as Apollo Medical's CEO?

9 employees have rated Apollo Medical CEO Thomas Lam on Glassdoor.com. Thomas Lam has an approval rating of 43% among Apollo Medical's employees. This puts Thomas Lam in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Apollo Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Apollo Medical investors own include PayPal (PYPL), SEA (SE), Mastercard (MA), NVIDIA (NVDA), Walt Disney (DIS), Lululemon Athletica (LULU), Enphase Energy (ENPH), Main Street Capital (MAIN), Square (SQ) and Exxon Mobil (XOM).

What is Apollo Medical's stock symbol?

Apollo Medical trades on the NASDAQ under the ticker symbol "AMEH."

Who are Apollo Medical's major shareholders?

Apollo Medical's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (10.68%), Vanguard Group Inc. (7.00%), State Street Corp (2.18%), Northern Trust Corp (0.72%), Dimensional Fund Advisors LP (0.72%) and Bank of New York Mellon Corp (0.63%). Company insiders that own Apollo Medical stock include Adrian Vazquez, Albert Waichow Young, Brandon Sim, Eric Chin, Physicians Of Californi Allied and Thomas S Lam.
View institutional ownership trends for Apollo Medical

Which major investors are selling Apollo Medical stock?

AMEH stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., First Trust Advisors LP, Invesco Ltd., SG Americas Securities LLC, Northern Trust Corp, Bank of New York Mellon Corp, D.A. Davidson & CO., and BNP Paribas Arbitrage SA.
View insider buying and selling activity for Apollo Medical
or view top insider-selling stocks.

Which major investors are buying Apollo Medical stock?

AMEH stock was purchased by a variety of institutional investors in the last quarter, including Steel Peak Wealth Management LLC, Nordea Investment Management AB, State Street Corp, Graham Capital Management L.P., Vanguard Group Inc., BlackRock Inc., Dimensional Fund Advisors LP, and Bridgewater Associates LP. Company insiders that have bought Apollo Medical stock in the last two years include Brandon Sim, Eric Chin, Physicians Of Californi Allied, and Thomas S Lam.
View insider buying and selling activity for Apollo Medical
or or view top insider-buying stocks.

How do I buy shares of Apollo Medical?

Shares of AMEH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Apollo Medical's stock price today?

One share of AMEH stock can currently be purchased for approximately $36.62.

How much money does Apollo Medical make?

Apollo Medical has a market capitalization of $2.05 billion and generates $773.91 million in revenue each year. The company earns $73.86 million in net income (profit) each year or $1.629990 on an earnings per share basis.

How many employees does Apollo Medical have?

Apollo Medical employs 1,133 workers across the globe.

What is Apollo Medical's official website?

The official website for Apollo Medical is www.apollomed.net.

How can I contact Apollo Medical?

Apollo Medical's mailing address is 1668 S. GARFIELD AVENUE 2ND FLOOR, ALHAMBRA CA, 91801. The company can be reached via phone at (626) 943-6491, via email at [email protected], or via fax at 818-839-5190.

This page was last updated on 5/29/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.